Metabolic Profiling of Nitrogen Metabolites for Unveiling the Protective Mechanisms of Active Peptide of Eupolyphaga Against Hyperlipidemia by UPLC-Q-Exactive HRMS/MS Analysis

Yanan Li,Hong Wang,Pingping Dong,Shengguang Wang,Huajian Li,Jing Xu,Peng Gao,Shaoping Wang,Long Dai
DOI: https://doi.org/10.2139/ssrn.4356656
2023-01-01
Abstract:Ethnopharmacological relevance: Eupolyphaga, as an edible insect with high protein, is a very famous animal traditional chinese medicine used for the treatment of cardiovascular diseases. Based on the previous work of our team and several studies, the therapeutic effect of the earthworm on hyperlipidemia has been found. However, the molecular mechanism of treatment remains indistinct.Aim of the study: The aim of this study was to prepare the Active Peptide of Eupolyphaga (APE) by bioenzyme hydrolysis, evaluate its effect on high-fat diet (HFD)-induced hyperlipidemia model rats, and further explore its protective mechanism.Material and methods: APE was prepared by bioenzymatic hydrolysis and its composition was characterized using multiple methods. A high-fat diet (HFD)-induced hyperlipidemia model was used to evaluate the modulatory effect of APE on hyperlipidemia. Normal diet-fed rats were taken as controls, and serum samples and livers were collected for biochemical and histopathological examinations. Then, to find out the anti-hyperlipidemic mechanism of APE, metabolic profiling of nitrogen metabolites in faeces and serum after treatment with APE (dose of 100 mg/kg) was performed by metabolomics. Results: The results of characterization experiments showed that pH of APE was 8.12 ± 0.26, and APE was a mixture within the determination results of peptide and sugar. The molecular weight of APE was concentrated at 90 - 1600 Da. Next, the rats by HFD induced increased hepatic lipids and blood lipid factors (p<0.05), different doses of APE could reverse the above phenomenon (p<0.05). For metabolomics results, the metabolic profiles of nitrogen metabolites in serum and feces from rats with HFD were significantly changed compared with normal diet-fed rats. Among them, 15 metabolites in feces and 12 metabolites in serum were significantly changed (p<0.05). After APE intervention, 4 nitrogen metabolites in feces were significantly up-regulated (p<0.05) and 11 metabolites were significantly down-regulated (p<0.05), 4 nitrogen metabolites in serum were significantly up-regulated (p<0.05) and 8 metabolites were significantly down-regulated (p<0.05). Indole and tryptophan (AUCs>0.85), which belong to tryptophan metabolism, should be potential biomarkers of APE against hyperlipidemia through enrichment and correlation analysis. Furthermore, APE could significantly down-regulated the mRNA expression of SREBP-1, SREBP-2, and HMGCR (p<0.05).Conclusions: Based on these results, we speculated that APE was able to treat hyperlipidemia by promoting the rate of tryptophan intestinal metabolism and affecting the contents of tryptophan and indole in vivo, thereby inhibiting the SREBPS/HMGCR pathway.
What problem does this paper attempt to address?